Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Khorashad · SciRah

Researcher profile · Semantic Scholar

J. Khorashad

Share profile

J. Khorashad — researcher profile on SciRah

h-index: 32
Works: 115
Citations: 5,127

Most-cited papers

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
D. Marin, A. Bazeos, F. Mahon, L. Eliasson +16 more
2010Journal of Clinical Oncology936 citations Open access
Semantic Scholar
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
H. de Lavallade, J. Apperley, J. Khorashad, D. Milojkovic +7 more
2008Journal of Clinical Oncology581 citations
Semantic Scholar
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
D. Marin, D. Milojkovic, E. Olavarría, J. Khorashad +11 more
2008Blood346 citations Open access
Semantic Scholar
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
M. Zabriskie, C. Eide, S. Tantravahi, N. A. Vellore +38 more
2014Cancer Cell344 citations Open access
Semantic Scholar
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.
Amr Ibrahim, L. Eliasson, J. Apperley, D. Milojkovic +14 more
2010Blood337 citations Open access
Semantic Scholar
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
J. Khorashad, T. Kelley, P. Szankasi, C. C. Mason +18 more
2013Blood235 citations Open access
Semantic Scholar
Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia
A. Eiring, B. Page, I. L. Kraft, C. C. Mason +22 more
2014Leukemia132 citations Open access
Semantic Scholar
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
D. Milojkovic, E. Nicholson, J. Apperley, T. Holyoake +12 more
2010Haematologica132 citations Open access
Semantic Scholar
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
J. Khorashad, D. Milojkovic, P. Mehta, M. Anand +10 more
2008Blood95 citations
Semantic Scholar
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Amr Ibrahim, Christos Paliompeis, M. Bua, D. Milojkovic +10 more
2010Blood68 citations Open access
Semantic Scholar
BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation
M. Alikian, G. Gerrard, P. Subramanian, Katherine Mudge +10 more
2012American journal of hematology/oncology66 citations Open access
Semantic Scholar
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
Georgios Nteliopoulos, A. Bazeos, S. Claudiani, G. Gerrard +12 more
2019Haematologica61 citations Open access
Semantic Scholar
SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA
D. Yan, Anca Franzini, A. Pomicter, Brayden J Halverson +27 more
2019Blood Cancer Discovery58 citations Open access
Semantic Scholar
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia
Graeme Smith, J. Apperley, D. Milojkovic, N. Cross +11 more
2020British Journal of Haematology56 citations Open access
Semantic Scholar
Advances in the treatment of chronic myeloid leukemia
A. Eiring, J. Khorashad, Kimberly A Morley, M. Deininger
2011BMC Medicine56 citations Open access
Semantic Scholar
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
S. Claudiani, J. Apperley, R. Gale, R. Clark +6 more
2017Haematologica53 citations Open access
Semantic Scholar
The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations.
Anca Franzini, A. Pomicter, D. Yan, J. Khorashad +5 more
2019Blood Advances44 citations Open access
Semantic Scholar
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
J. Khorashad, A. Eiring, C. C. Mason, Kevin C. Gantz +17 more
2015Blood44 citations Open access
Semantic Scholar
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia
S. Claudiani, J. Apperley, Richard Szydlo, Afzal Khan +8 more
2020British Journal of Haematology42 citations
Semantic Scholar
Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma
Ching Ngar Wong, Petros Fessas, Kathy Dominy, F. Mauri +7 more
2020Liver international (Print)42 citations Open access
Semantic Scholar
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B
Alfonso E Bencomo-Alvarez, Andres J. Rubio, Idaly M. Olivas, Mayra A Gonzalez +13 more
2021Oncogene40 citations Open access
Semantic Scholar
A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia
Seyed Mohammadreza Bolandi, Mahdi Pakjoo, Peyman Beigi, M. Kiani +4 more
2021Cells40 citations Open access
Semantic Scholar
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
A. Eiring, J. Khorashad, David J Anderson, F. Yu +13 more
2015Leukemia40 citations Open access
Semantic Scholar
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
Mustafa Daghistani, D. Marin, J. Khorashad, Lihui Wang +10 more
2010Blood39 citations Open access
Semantic Scholar
NUCLEAR-CYTOPLASMIC TRANSPORT IS A THERAPEUTIC TARGET IN MYELOFIBROSIS
D. Yan, A. Pomicter, S. Tantravahi, C. C. Mason +22 more
2018Clinical Cancer Research38 citations Open access
Semantic Scholar
Technical aspects and clinical applications of measuring BCR‐ABL1 transcripts number in chronic myeloid leukemia
L. Foroni, G. Gerrard, E. Nna, J. Khorashad +6 more
2009American journal of hematology/oncology38 citations Open access
Semantic Scholar
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia.
H. de Lavallade, P. Finetti, N. Carbuccia, J. Khorashad +7 more
2010Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis35 citations
Semantic Scholar
Does a rise in the BCR‐ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
D. Marin, J. Khorashad, L. Foroni, D. Milojkovic +6 more
2009British Journal of Haematology30 citations
Semantic Scholar
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors
A. Corbin, T. O'Hare, Z. Gu, I. L. Kraft +9 more
2013Cancer Research27 citations Open access
Semantic Scholar
Germline predisposition to haematological malignancies: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene‐CanVar and the NHS England Haematological Oncology Working Group
B. Speight, H. Hanson, C. Turnbull, Steven I Hardy +12 more
2023British Journal of Haematology23 citations Open access
Semantic Scholar
A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia
S. Tantravahi, P. Szankasi, J. Khorashad, Kim-Hien T. Dao +3 more
2016Leukemia and Lymphoma21 citations Open access
Semantic Scholar
What challenges remain in chronic myeloid leukemia research?
A. Carella, S. Branford, M. Deininger, F. Mahon +5 more
2013Haematologica20 citations Open access
Semantic Scholar
Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.
A. Bazeos, J. Khorashad, F. Mahon, L. Eliasson +13 more
200919 citations
Semantic Scholar
MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common β Chain Cytokine Receptor Endocytosis.
Helong Zhao, A. Pomicter, A. Eiring, Anca Franzini +24 more
2021Blood14 citations Open access
Semantic Scholar
The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas
Niyaz Zaman, S. Dass, Persephone du Parcq, S. Macmahon +4 more
2020Cancer Genomics & Proteomics14 citations Open access
Semantic Scholar
The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies
D. Milojkovic, G. Gerrard, Christos Paliompeis, M. Bua +7 more
201113 citations
Semantic Scholar
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
J. Khorashad, S. Wagner, L. Greener, D. Marin +12 more
2009Haematologica13 citations Open access
Semantic Scholar
Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia
J. Khorashad, Siân Rizzo, A. Tonks
2024Cancer Drug Resistance12 citations Open access
Semantic Scholar
Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
S. Claudiani, J. Apperley, Afzal Khan, J. Khorashad +1 more
2020Haematologica12 citations Open access
Semantic Scholar
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
S. Claudiani, A. Gatenby, Richard Szydlo, G. Nesr +7 more
2019Haematologica12 citations Open access
Semantic Scholar
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
A. Eiring, B. Page, I. L. Kraft, C. C. Mason +22 more
2017Leukemia12 citations Open access
Semantic Scholar
Duplex quantitative PCR for molecular monitoring of BCR‐ABL1‐associated hematological malignancies
G. Gerrard, Katherine Mudge, R. Stewart, P. Foskett +9 more
2011American journal of hematology/oncology12 citations
Semantic Scholar
Assessment of quantitative polymerase chain reaction for BCR–ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Kathy Dominy, S. Claudiani, M. O'Hare, Richard Szydlo +6 more
2022British Journal of Haematology11 citations
Semantic Scholar
Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML).
S. Claudiani, S. Metelli, Rafiee Kamvar, Richard Szydlo +12 more
2019Blood11 citations Open access
Semantic Scholar
Alginate foam-based three-dimensional culture to investigate drug sensitivity in primary leukaemia cells
M. Karimpoor, Eva Yebra‐Fernandez, M. Parhizkar, Mine Orlu +3 more
2018Journal of the Royal Society Interface11 citations Open access
Semantic Scholar
Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia
S. Claudiani, J. Apperley, S. Deplano, J. Khorashad +4 more
2016American journal of hematology/oncology10 citations Open access
Semantic Scholar
Variant Isoforms of BCR-ABL1 in Chronic Myelogenous Leukemia Reflect Alternative Splicing of ABL1 in Normal Tissue – Letter
J. Khorashad, D. Milojkovic, A. Reid
2010Molecular Cancer Therapeutics10 citations
Semantic Scholar
BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.
A. Bazeos, David Marin, G. Gerrard, Richard Szydlo +7 more
200910 citations
Semantic Scholar
Selection of therapy: Rational Decisions Based on Molecular Events
J. Khorashad, M. Deininger
2011Hematology/Oncology Clinics of North America8 citations Open access
Semantic Scholar
Development of artificial bone marrow fibre scaffolds to study resistance to anti‐leukaemia agents
M. Karimpoor, E. IIlangakoon, A. Reid, S. Claudiani +2 more
2018British Journal of Haematology7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Milojkovic×26
Invite
D. Milojkovic — researcher profile on SciRah
J. Apperley×25
Invite
J. Apperley — researcher profile on SciRah
L. Foroni×24
Invite
L. Foroni — researcher profile on SciRah
A. Reid×20
Invite
A. Reid — researcher profile on SciRah

×16

Invite

D. Marin — researcher profile on SciRah

Invite

J. Goldman — researcher profile on SciRah

Richard Szydlo×15

Invite

Richard Szydlo — researcher profile on SciRah

Invite

A. Eiring — researcher profile on SciRah

M. Deininger×13

Invite

M. Deininger — researcher profile on SciRah

A. Pomicter×11

Invite

A. Pomicter — researcher profile on SciRah

Invite

T. O'Hare — researcher profile on SciRah

Invite

G. Gerrard — researcher profile on SciRah